drugset / Trial / NCT00158873

Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects

NCT00158873

Phase 4 Completed 224 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.

Timeline

Start
2004-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified
Subject Lorazepam Small molecule
Subject Midazolam Small molecule
Subject Morphine Other / unclassified
Subject Propofol Small molecule
Subject Remifentanil Small molecule

Indications

No indication recorded.